IL300374A - A method for treating diseases related to WWOX - Google Patents

A method for treating diseases related to WWOX

Info

Publication number
IL300374A
IL300374A IL300374A IL30037423A IL300374A IL 300374 A IL300374 A IL 300374A IL 300374 A IL300374 A IL 300374A IL 30037423 A IL30037423 A IL 30037423A IL 300374 A IL300374 A IL 300374A
Authority
IL
Israel
Prior art keywords
wwox
promoter
gene
brain
mice
Prior art date
Application number
IL300374A
Other languages
English (en)
Hebrew (he)
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of IL300374A publication Critical patent/IL300374A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL300374A 2020-08-11 2021-08-11 A method for treating diseases related to WWOX IL300374A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064181P 2020-08-11 2020-08-11
US202163167277P 2021-03-29 2021-03-29
PCT/IL2021/050982 WO2022034591A1 (en) 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases

Publications (1)

Publication Number Publication Date
IL300374A true IL300374A (en) 2023-04-01

Family

ID=77910831

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300374A IL300374A (en) 2020-08-11 2021-08-11 A method for treating diseases related to WWOX

Country Status (9)

Country Link
US (1) US20230293726A1 (enExample)
EP (2) EP4582143A3 (enExample)
JP (1) JP7850136B2 (enExample)
KR (1) KR20230051223A (enExample)
AU (1) AU2021324538A1 (enExample)
CA (1) CA3188895A1 (enExample)
ES (1) ES3032462T3 (enExample)
IL (1) IL300374A (enExample)
WO (1) WO2022034591A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463413B (zh) * 2023-06-12 2023-10-03 佛山科学技术学院 猪间性病相关的wwox基因分子标记及其应用
WO2025264815A1 (en) * 2024-06-18 2025-12-26 Synaptec Network, Inc. Systems and methods of exosome mediated delivery of antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
DK2282779T3 (da) * 2008-04-29 2013-05-27 Pharnext Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
WO2017147720A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating a central nervous system disorder
KR20210053877A (ko) * 2018-06-26 2021-05-12 리보노바 인크. 미토콘드리아 기능장애를 치료하는 방법
KR20220094216A (ko) * 2019-11-08 2022-07-05 코브 테라퓨틱스 변형된 아데노-관련 바이러스 벡터 및 이의 중추신경계로의 전달

Also Published As

Publication number Publication date
ES3032462T3 (en) 2025-07-18
EP4582143A2 (en) 2025-07-09
KR20230051223A (ko) 2023-04-17
CA3188895A1 (en) 2022-02-17
EP4196595B1 (en) 2025-03-12
WO2022034591A1 (en) 2022-02-17
JP2023537093A (ja) 2023-08-30
EP4196595A1 (en) 2023-06-21
US20230293726A1 (en) 2023-09-21
JP7850136B2 (ja) 2026-04-22
EP4582143A3 (en) 2025-10-22
AU2021324538A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
Steinberg et al. Modeling genetic epileptic encephalopathies using brain organoids
Liu et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo
Mei et al. Stage-specific deletion of Olig2 conveys opposing functions on differentiation and maturation of oligodendrocytes
Repudi et al. Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects
Tung et al. Mir-17∼ 92 confers motor neuron subtype differential resistance to ALS-associated degeneration
Nishino et al. A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties
US20190099452A1 (en) Methods for promoting oligodendrocyte regeneration and remyelination
US10119123B2 (en) Cell fate conversion of differentiated somatic cells into glial cells
US20190322981A1 (en) Means and methods for the generation of oligodendrocytes
EP4196595B1 (en) Method for the treatment of wwox associated diseases
US20240108758A1 (en) Compounds, compositions, and methods for using hla-f
IL279150B1 (en) Neural stem cell preparations and cultivation methods in degenerative neurological disorders
US20210228741A1 (en) Methods and compositions to stimulate retinal regeneration
Deng et al. Let-7f promotes the differentiation of neural stem cells in rats
CN111686124B (zh) miR-486-3p在制备治疗SAH导致的神经炎症产品中的应用
Liu et al. Single‐Cell RNA Sequencing Uncovers Molecular Features Underlying the Disrupted Neurogenesis Following Traumatic Brain Injury
CN116457025A (zh) 用于治疗wwox相关疾病的方法
Fu et al. Comparative transcriptomic profiling reveals a role for Olig1 in promoting axon regeneration
Obeid et al. Neuron-Specific WWOX Gene Therapy Produces Dose-Dependent, Durable Rescue in a Model of WWOX-Related Epileptic Encephalopathy
Africano Transcriptomic analysis of the effects of PHOX2B polyAla expansions in cellular models of Congenital Central Hypoventilation Syndrome
Alarcon-Martineza et al. Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina
Gomes et al. Innate immunocompetent iNSpheroids: A hiPSC-derived 3D model to study the central nervous system captures an early CNS response to rAAV
Vaculik Beclin1 regulates adult hippocampal neurogenesis
Lim Investigating developmental and functional deficits in neurodegenerative disease using transcriptomic analyses
Jayadev et al. The p53 Transcription Factor Modulates